173 related articles for article (PubMed ID: 18363211)
41. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Chen MH
Curr Cardiol Rep; 2009 May; 11(3):167-74. PubMed ID: 19379636
[TBL] [Abstract][Full Text] [Related]
42. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001
[No Abstract] [Full Text] [Related]
43. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.
Zhu Y; Li H; Yao XD; Zhang SL; Zhang HL; Shi GH; Yang LF; Yang ZY; Wang CF; Ye DW
Urol Int; 2010; 85(3):334-40. PubMed ID: 20980789
[TBL] [Abstract][Full Text] [Related]
44. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
[TBL] [Abstract][Full Text] [Related]
45. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
46. Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Minor DR
J Clin Oncol; 2010 Oct; 28(30):e619; author reply e620. PubMed ID: 20733133
[No Abstract] [Full Text] [Related]
47. Trials probe new agents for kidney cancer.
Hampton T
JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
[No Abstract] [Full Text] [Related]
48. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Coriat R; Ropert S; Mir O; Billemont B; Chaussade S; Massault PP; Blanchet B; Vignaux O; Goldwasser F
Invest New Drugs; 2011 Oct; 29(5):1090-3. PubMed ID: 20524036
[TBL] [Abstract][Full Text] [Related]
49. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Lenihan DJ
J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
[No Abstract] [Full Text] [Related]
50. Newly approved therapies for RCC and their effect on the standard of care.
Figlin RA
Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
[No Abstract] [Full Text] [Related]
51. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
52. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Porta C; Paglino C; Imarisio I; Bonomi L
Clin Exp Med; 2007 Dec; 7(4):127-34. PubMed ID: 18188524
[TBL] [Abstract][Full Text] [Related]
53. Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
Westgeest HM; van Erp NP; Honeywell RJ; Hoekstra R; Peters GJ; Verheul HM
J Clin Oncol; 2013 Feb; 31(6):e83-6. PubMed ID: 23182994
[No Abstract] [Full Text] [Related]
54. Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
Di Lorenzo G
Eur Urol; 2007 Sep; 52(3):926-8; author reply 928. PubMed ID: 17574728
[No Abstract] [Full Text] [Related]
55. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
56. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Rini BI; Sosman JA; Motzer RJ
BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
[No Abstract] [Full Text] [Related]
57. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Turan N; Benekli M; Ozturk SC; Inal S; Memis L; Guz G; Cetin B; Buyukberber S
Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
[TBL] [Abstract][Full Text] [Related]
58. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
[TBL] [Abstract][Full Text] [Related]
59. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Je Y; Schutz FA; Choueiri TK
Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
[TBL] [Abstract][Full Text] [Related]
60. Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib.
Prescrire Int; 2007 Aug; 16(90):141-3. PubMed ID: 17724834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
